A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms Protocol 9785-CL-0123
- Sponsors Astellas Pharma Global Development
- 08 Mar 2024 This trial has been Completed in Greece, According to European Clinical Trials Database record.
- 31 Oct 2023 Planned End Date changed from 30 Sep 2025 to 31 Jul 2026.
- 31 Oct 2023 Planned primary completion date changed from 30 Sep 2025 to 31 Jul 2026.